Schering antifungal
Executive Summary
SCH-39304 has entered Phase II trials for treatment of serious systemic fungal infections including Candida, cryptococcal meningitis, Aspergillus and Trichophyton - infections frequently occurring in cancer patients undergoing chemotherapy as well as AIDS patients. The product will likely compete in the U.S. market against Pfizer's Diflucan (fluconazole), for which an NDA is currently pending. SCH-39304 is licensed from the Japanese firm Sumitomo, which has retained marketing rights for Japan and certain Far East countries....
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.